Lentiviral Vectors for the Engineering of Implantable Cells Secreting Recombinant Antibodies.
The implantation of genetically modified cells is considered for the chronic delivery of therapeutic recombinant proteins in vivo. In the context of gene therapy, the genetic engineering of cells faces two main challenges. First, it is critical to generate expandable cell sources, which can maintain stable high productivity of the recombinant protein of interest over time, both in culture and after transplantation. In addition, gene transfer techniques need to be developed to engineer cells synthetizing complex polypeptides, such as recombinant monoclonal antibodies, to broaden the range of potential therapeutic applications. Here, we provide a workflow for the use of lentiviral vectors as a flexible tool to generate antibody-producing cells. In particular, lentiviral vectors can be used to genetically engineer the cell types compatible with encapsulation devices protecting the implanted cells from the host immune system. Detailed methods are provided for the design and production of lentiviral vectors, optimization of cell transduction, as well as for the quantification and quality control of the produced recombinant antibody.
Brain Mind Institute, Ecole Polytechnique Fédérale de Lausanne (EPFL), Station 19, 1015, Lausanne, Switzerland.
Aurélien
A
Lathuilière
Brain Mind Institute, Ecole Polytechnique Fédérale de Lausanne (EPFL), Station 19, 1015, Lausanne, Switzerland. bernard.schneider@epfl.ch.
Bernard L
BL
Schneider
D000921:Antibody-Producing Cells / Q000276:immunology* / Q000378:metabolism; D018014:Gene Transfer Techniques; D005818:Genetic Engineering / Q000379:methods; D005822:Genetic Vectors; D006801:Humans; D016086:Lentivirus / Q000235:genetics*; D011994:Recombinant Proteins / Q000235:genetics* / Q000276:immunology; D014161:Transduction, Genetic / Q000379:methods*
D011994:Recombinant Proteins
Cell encapsulation; Cell transplantation; Chronic delivery; Ex vivo gene therapy; Recombinant antibodies